HI,just reading through PA2000's post. Looks like he was taken...

HI,

just reading through PA2000's post. Looks like he was taken in by CYT's letter hook-line-and-sinker.

In particular:
"Avx and the BOD are only offering you a share of the costly ph3 with big risk"

Simple question for Pa2000:
Why would you be a shareholder in a speculative bio-tech company if you DIDN'T want to take on the risk of phase III trials?

Is cytopia saying that their drug is so special it doesn't need phase III? Or is PA2000 hoping that PGL will use their money to buy the rights to an existing tested drug? Or has CYT and PA lost the plot?

It's clearly about money, and CYT wants to get its hands on PGLs money, rather than AVX. AVX is far more advanced than CYT, with the recent 96 week AVX results demonstrating efficacy that has not been seen before in any competitor drug. Reading through PGL's history it was the emergence of a competitor that put the nail in the coffin for their pathway project and PI-88. So, personally I can't see a similarity between PI-88 and ATC that PA2000 and CYT attempt to draw.

If PA-2000 wants to avoid risky phaseIII trials, then he should examine becoming a shareholder in Cochlear rather than PGL, CYT, PXS, AVX, etc.


Joel